Xing-Hui Lai

Tumor-specific in situ IL-12 expression combined with αPD-L1 suppresses melanoma growth by remodeling the tumor immune microenvironment.

Interleukin-12 (IL-12) potently activates antitumor immune responses and compensates for the challenge of insufficient T cell activation and infiltration faced in immune checkpoint therapy. However, its clinical application is limited by severe systemic toxicity and the upregulation of PD-L1 on tumor cells during treat...